Literature DB >> 35771419

Co-immunoprecipitation of Protein Complexes from Different Subcellular Compartments in Vasculogenic Mimicry Studies.

Daniel Delgado-Bellido1,2, Angel Garcia-Diaz1,2, Francisco Javier Oliver3,4.   

Abstract

Aberrant extravascular expression of VE-cadherin has been observed in metastasis associated with vasculogenic mimicry (VM); we have recently shown that in VM prone cells VE-cadherin (mainly in the form of phospho-VE-cadherin in Y658) is in part located in the cell nucleus, which associates with p120-catenin and the transcription factor kaiso allowing increased plasticity that potentiates VM development in malignant cells. In this chapter, we describe the protocol to analyze protein-protein interactions in subcellular fractions with particular focus in VE-cadherin. The verification of the subcellular interactome of VE-cadherin and other key proteins involved in VM shed light to novel functions of endothelial proteins aberrantly expressed in tumor cells and their consequences in cell plasticity during VM development.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Immunoprecipitation; Protein complexes; VE-cadherin; Vasculogenic mimicry

Mesh:

Substances:

Year:  2022        PMID: 35771419     DOI: 10.1007/978-1-0716-2403-6_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  15 in total

Review 1.  Mass spectrometry-based proteomics.

Authors:  Ruedi Aebersold; Matthias Mann
Journal:  Nature       Date:  2003-03-13       Impact factor: 49.962

Review 2.  VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity.

Authors:  Monica Giannotta; Marianna Trani; Elisabetta Dejana
Journal:  Dev Cell       Date:  2013-09-16       Impact factor: 12.270

Review 3.  Nuclear signaling from cadherin adhesion complexes.

Authors:  Pierre D McCrea; Meghan T Maher; Cara J Gottardi
Journal:  Curr Top Dev Biol       Date:  2015-02-12       Impact factor: 4.897

4.  Protein-Protein Interactions: Co-Immunoprecipitation.

Authors:  Jer-Sheng Lin; Erh-Min Lai
Journal:  Methods Mol Biol       Date:  2017

5.  VE-cadherin promotes vasculogenic mimicry by modulating kaiso-dependent gene expression.

Authors:  Daniel Delgado-Bellido; Mónica Fernández-Cortés; María Isabel Rodríguez; Santiago Serrano-Sáenz; Arkaitz Carracedo; Angel Garcia-Diaz; F Javier Oliver
Journal:  Cell Death Differ       Date:  2018-05-21       Impact factor: 15.828

Review 6.  Vasculogenic mimicry.

Authors:  Robert Folberg; Andrew J Maniotis
Journal:  APMIS       Date:  2004 Jul-Aug       Impact factor: 3.205

7.  Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry.

Authors:  A J Maniotis; R Folberg; A Hess; E A Seftor; L M Gardner; J Pe'er; J M Trent; P S Meltzer; M J Hendrix
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

8.  VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry.

Authors:  Angela R Hess; Elisabeth A Seftor; Lynn M Gruman; Michael S Kinch; Richard E B Seftor; Mary J C Hendrix
Journal:  Cancer Biol Ther       Date:  2006-02-14       Impact factor: 4.742

9.  CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of β-catenin and E-cadherin.

Authors:  Yaowu He; Claire M Davies; Brittney S Harrington; Linh Hellmers; Yonghua Sheng; Amy Broomfield; Thomas McGann; Kate Bastick; Laurie Zhong; Andy Wu; Grace Maresh; Shannon McChesney; Kuan Yau Wong; Mark N Adams; Ryan C Sullivan; James S Palmer; Lez J Burke; Adam D Ewing; Xin Zhang; David Margolin; Li Li; Rohan Lourie; Admire Matsika; Bhuvana Srinivasan; Michael A McGuckin; John W Lumley; John D Hooper
Journal:  Oncogene       Date:  2019-08-30       Impact factor: 9.867

10.  An aberrant nuclear localization of E-cadherin is a potent inhibitor of Wnt/β-catenin-elicited promotion of the cancer stem cell phenotype.

Authors:  Y-J Su; Y-W Chang; W-H Lin; C-L Liang; J-L Lee
Journal:  Oncogenesis       Date:  2015-06-15       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.